Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.
Today at the 25th World Congress of Dermatology WCD Boehringer Ingelheim presented new latebreaking data from the EFFISAYIL 2 trial showing that spesolimab significantly reduced the risk of GPP flares by 84 over 48 weeks compared to placebo.
Cyndy B. Galimpin, general manager of Boehringer Ingelheim Vietnam, spoke with VIR’s Bich Ngoc about the group's development strategy for the next few years.
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer...
Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.